Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Changes in self-schema structure in cognitive therapy for major depressive disorder: a randomized clinical trial.
Negative cognitive structure ( particularly for interpersonal content ) has been shown in some research to persist past a current episode of depression and potentially to be a stable marker of vulnerability for depression ( D. J. A. Dozois , 2007 ; D. J. A. Dozois & K. S. Dobson , 2001a ) . Given that cognitive therapy ( CT ) is highly effective for treating the acute phase of a depressive episode and that this treatment also reduces the risk of relapse and recurrence , it is possible that CT may alter these stable cognitive structures . In the current study , patients were r and omly assigned to CT+ pharmacotherapy ( n = 21 ) or to pharmacotherapy alone ( n = 21 ) . Both groups evidence d significant and similar reductions in level of depression ( as measured with the Beck Depression Inventory-II and the Hamilton Rating Scale for Depression ) , as well as automatic thoughts and dysfunctional attitudes . However , group differences were found on cognitive organization in favor of individuals who received the combination of CT+ pharmacotherapy . The implication s of these results for underst and ing mechanisms of change in therapy and the prophylactic nature of CT are discussed
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .